America Must Win the Biotech Race Against China

RealClearDefense | Rob Maness

China currently supplies key starting materials for hundreds of United States-approved medicines, leveraging heavy state subsidies to dominate global active pharmaceutical ingredient supply chains. This reliance creates severe strategic vulnerabilities during geopolitical crises, where access to pharmaceuticals equals fuel or food in operational importance. Beijing is rapidly expanding into frontier biotechnology through centralized clinical trial networks and streamlined regulatory pathways.

Chinese biotech licensing deals reached nearly $138 billion last year—a nearly tenfold surge over four years—while China captured nearly one-third of global clinical trial starts. In response, retired United States Air Force Colonel Rob Maness advocates integrating foreign early-stage trial data into American regulatory pipelines alongside domestic industrial reforms. Regulatory delays stall progress. Accelerating domestic permitting, protecting intellectual property, and expanding trial initiatives like Operation TrialBlazer are essential to secure Western pharmaceutical resilience and preserve technological dominance against strategic competitors.

Comment

Monopolisation of active pharmaceutical ingredients directly threatens the operational readiness of the United States Defense Health Agency during campaign planning for the Indo-Pacific theatre. Relying on single-source foreign chemical precursors for combat-essential pharmaceuticals leaves forward-deployed formations vulnerable to strategic supply denial before combat operations even commence. Because biological manufacturing bottlenecks cannot be resolved on tactical timelines, peacetime precursor concentration functions as an asymmetric leveller against Western carrier strike groups.

This industrial vulnerability mirrors the Allied crisis of 1942, when the loss of East Asian rubber plantations forced the United States Rubber Reserve Company to crash-build synthetic production capacity to sustain military transport. Without equivalent state-backed industrial restructuring, the Strategic National Stockpile remains structurally exposed to maritime interdiction across East Asian sea lines of communication.

Strategic Question for Discussion

Which presents the greater operational bottleneck during a prolonged Indo-Pacific crisis — the physical vulnerability of Pacific sea lines of communication or the Defense Health Agency's reliance on foreign-sourced active pharmaceutical ingredients?

The available evidence points toward upstream chemical supply dependency as the more immediate operational bottleneck, as interdiction occurs at the source prior to any maritime transit. While escorting shipping through contested sea lines of communication remains a core naval mission, no tactical posture can mitigate the total absence of primary pharmaceutical precursors before synthesis even begins.

Share your assessment in the comments below.

Read the original article